Ações da Amgen sobem com expansão do pipeline e fortes resultados no 4º trimestre
As ações da Amgen subiram 35% nos últimos seis meses e são negociadas perto de US$ 388, impulsionadas por resultados sólidos no 4º trimestre de 2025 e pela expansão do pipeline em oncologia. Analistas elevaram seus preços-alvo após receitas e lucro por ação acima do consenso, com avanços em programas como IMDELLTRA e LUMAKRAS.
Amgen shares have risen approximately 35% over the past six months, recently trading near $388 per share after touching $390, the top of its 52-week range. The rally reflects growing investor confidence in the company's oncology pipeline expansion, durable profitability profile, and continued institutional participation.
An investment firm raised its price target on Amgen shares to $432 from $381 while maintaining an Overweight rating. The price target increase reflects updated modeling following Amgen's fourth-quarter 2025 results, which showed the company achieved nearly 10% revenue growth over the last twelve months. The revision incorporates higher sales estimates for Uplizna and Tezspire.
Amgen reported fourth-quarter revenue of $9.87 billion, surpassing the consensus estimate of $9.47 billion. The company's earnings per share came in at $5.29, exceeding the expected $4.73. Strong sales of products like Prolia, Repatha, Evenity, and Uplizna significantly contributed to these results.
At a virtual oncology leadership summit this week, management emphasized that IMDELLTRA is now administered at more than 1,600 U.S. sites following full approval in second-line small cell lung cancer, with three additional Phase III trials underway across first-line and limited-stage settings. A senior executive stated the company wants to bring the value of this modality to the whole spectrum of the disease, reinforcing expansion plans that significantly increase the drug's long-term addressable opportunity.
LUMAKRAS is advancing into earlier-line lung and colorectal cancer Phase III trials, while xaluritamig remains in pivotal development in prostate cancer with overall survival endpoints in both post-taxane and pre-taxane settings.
A firm hosted a fireside chat with Amgen senior management covering expansion opportunities for Uplizna and the ongoing Phase II study of inhalable TSLP-directed treatment AMG 104. Management also discussed daxdilimab following positive Phase II results in discoid lupus erythematosus and the Phase III program for dazodalibep in Sjogren's syndrome.
Amgen maintains strong underlying profitability, with gross margins near 71% and EBIT margins above 30%, reinforcing earnings durability into 2026. The company's market capitalization stands at $201.27 billion.
Institutional filings show active positioning. Andra AP fonden increased its stake by 306.9% to 47,200 shares worth about $13.32 million, Mitsubishi UFJ Asset Management raised its holdings by 3.7% to 1,237,508 shares valued at roughly $349 million, and Sumitomo Mitsui Financial Group boosted its position by 7.8% to 75,779 shares. Primecap Management trimmed its stake by 8.7% but still owns 9,707,609 shares worth about $2.74 billion, while Argent Trust reduced its position by 29.4% and Erste Asset Management cut its stake by 21.6%.
Following the earnings report, multiple firms adjusted their price targets. One firm raised its price target for Amgen to $360, maintaining an Outperform rating. Another firm increased its price target to $350, citing a top-line beat of $396 million and earnings per share that exceeded expectations by 60 cents. A third firm adjusted its price target to $347, noting the solid earnings and fiscal year 2026 guidance that surpassed expectations. One firm reiterated an Underperform rating with a price target of $304.